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 SCIENTIFIC OPINION  
Scientific Opinion on the safety and efficacy of Hostazym X (endo-1,4-beta-
xylanase) as a feed additive for poultry, piglets and pigs for fattening
1 
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Hostazym  X  is  an  enzyme  preparation  of  xylanase  produced  by  a  non-genetically  modified  strain  of 
Trichoderma citrinoviride. The fermentation product showed negative results in a bacterial reverse mutation 
assay. The results of an in vitro chromosomal aberration test and of an in vivo comet assay indicate the presence 
of genotoxic activity in the product. Although the tolerance studies provided in target species did not indicate 
any  adverse  effect  of  the  additive,  the  FEEDAP  Panel,  taking  into  account  the  genotoxic  hazard  from  the 
product, cannot conclude on the safety of the additive for the target species. The results obtained in a subchronic 
rat study did not indicate any concerns for consumer safety. However, owing to the lack of information on the 
nature  and  fate  of  potentially  genotoxic  material  in  food  derived  from  animals  receiving  the  additive,  the 
FEEDAP  Panel  cannot  conclude  on  the  safety  of  the  additive  for  the  consumer.  The  product  should  be 
considered a potential skin and eye irritant, and a potential skin and respiratory sensitiser. Owing to the presence 
of genotoxic activity in the product, any level of exposure to the additive is considered hazardous. No risks to the 
environment are expected to result from the use of the additive in feed, and, therefore, no further environmental 
risk assessment is required. Based on the results obtained in the efficacy studies, the FEEDAP Panel concludes 
that the additive has the potential to be efficacious in turkeys for fattening at the dose of 1 050 EPU/kg feed and 
in chickens for fattening, laying hens, piglets (weaned) and pigs for fattening at the dose of 1 500 EPU/kg feed. 
Conclusions on the efficacy can be extrapolated to minor poultry species.  
© European Food Safety Authority, 2013 
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SUMMARY 
Following  a  request  from  the  European  Commission,  the  Panel  on  Additives  and  Products  or 
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and 
efficacy of Hostazym X, endo-1,4-beta-xylanase (xylanase), as a feed additive for poultry, piglets 
(weaned) and pigs for fattening. Hostazym X is an enzyme preparation containing xylanase, produced 
by a non-genetically modified strain of Trichoderma citrinoviride, presented in four different final 
formulations (two liquid and two solid).  
The fermentation product that is used to prepare the additive showed negative results in a bacterial 
reverse mutation assay. However, the results of an in vitro chromosomal aberration test and of an in 
vivo  comet  assay  indicate  the  presence  of  genotoxic  activity.  Since  the  identity  and  fate  of  the 
substance causing this effect is unknown, the risk to the target species, consumers and users cannot be 
identified. 
Tolerance studies in chickens and turkeys for fattening, laying hens and piglets were provided. The 
results of these studies showed that a dose 100 times the dose of 3 000 EPU/kg (i.e. 300 000EPU/kg 
feed) was well tolerated by the animals. The FEEDAP Panel considers that conclusions reached in the 
major poultry species can be extrapolated to minor poultry species provided that the same maximum 
dose applies (3 000 EPU/kg feed). Similarly, the conclusions reached in piglets can be extended to 
pigs for fattening at the same maximum dose. The tolerance studies did not indicate any adverse 
effects of the additive. Nevertheless, considering the genotoxic hazard from the product, the FEEDAP 
Panel cannot conclude on the safety of the additive for the target species. 
Although the results obtained in a subchronic rat study did not indicate any concerns for consumer 
safety arising from the use of Hostazym X as a feed additive, owing to the genotoxic activity present 
in the product, the FEEDAP Panel cannot conclude on the safety of the additive for the consumer. 
No specific studies to address the safety for the user were provided by the applicant; consequently, the 
additive should be considered a potential skin and eye irritant, and a potential skin and respiratory 
sensitiser. Persons handling the additive may be in direct contact with it. Therefore, the conclusions 
reached regarding the genotoxicity effect of the product need to be taken into account. The FEEDAP 
Panel considers that any level of exposure to the additive is hazardous. 
The  active  substance  present  in  the  additive  (xylanase)  is  a  protein  and  as  such  will  be 
degraded/inactivated during the passage through the digestive tract of animals. Therefore, no risks to 
the environment are expected.  
Based on the results obtained in the efficacy studies, the FEEDAP Panel concludes that the additive 
has the potential to be efficacious in turkeys for fattening at the dose of 1 050 EPU/kg feed and in 
chickens  for  fattening,  laying  hens,  piglets  (weaned)  and  pigs  for  fattening  at  the  dose  of  1 500 
EPU/kg feed. The FEEDAP Panel considers that the conclusions on the efficacy drawn from the 
studies provided in major poultry species can be extrapolated to all other minor poultry species for 
fattening and laying. The dose that is considered efficacious in minor growing poultry species is 1 050 
EPU/kg feed and in minor laying poultry species is 1 500 EPU/kg feed.  Hostazym X for poultry, piglets and pigs for fattening 
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BACKGROUND 
Regulation  (EC)  No  1831/2003
4  establishes the rules governing the Community authorisation of 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an 
application in accordance with Article 7. Article 10(2) of that Regulation also specifies that for 
existing products within the meaning of Article 10(1), an application shall be submitted in accordance 
with Article 7, at the latest one year before the expiry date of the authorisation given pursuant to 
Directive 70/524/EEC for additives with a limited authorisation period, and within a maximum of 
seven years after the entry into force of this Regulation for additives authorised without a time limit or 
pursuant to Directive 82/471/EEC. 
The European Commission received a request from  the company HuvePharma NV
5 for re-evaluation 
and for authorisation of a new use of the product Hostazym X, endo-1,4-beta-xylanase, when used as a 
feed additive for chickens for fattening, turkeys for fattening, laying hens, weaned piglets, fattening 
pigs and other birds for fattening or laying   (category:  zootechnical additive; functional group: 
digestibility enhancers) under the conditions mentioned in Table 1.  
According  to  Article  7(1)  of  Regulation  (EC)  No  1831/2003,  the  Commission  forwarded  the 
application to the European Food Safety Authority (EFSA) as an application under Article 4(1) 
(authorisation of a feed additive or new use of a feed additive) and under Article 10(2) (re-evaluation 
of an authorised feed additive). EFSA received directly from the applicant the technical dossier in 
support of this application.
6 According to Article 8 of that Regulation, EFSA,  after verifying the 
particulars and documents submitted by the applicant, shall undertake an assessment in order to 
determine whether the feed additive complies with the conditions laid down in Article 5. The 
particulars and documents in support of the application were considered valid by EFSA as of 24 June 
2010. 
The additive Hostazym X is a preparation of endo -1,4-beta-xylanase produced by a non-genetically 
modified  strain  of   Trichoderma  citrinoviride  Bisset  formerly  identified  as  Trichoderma 
longibrachiatum (IM SD135). This product, a liquid and a solid formulation, is currently authorised as 
a feed additive for chickens for fattening,
7 turkeys for fattening,
8 laying hens and piglets (weaned).
9  
The Scientific Committee on Animal Nutrition released an opinion on the safety of the product for the 
chickens for fattening, laying hens and piglets, consumers, users and the environment (EC, 2002). 
TERMS OF REFERENCE 
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the 
safety for the target animals, consumer, user and the environment and the efficacy of the product 
Hostazym X (endo-1,4-beta-xylanase), when used under the conditions described in Table 1. 
                                                       
4   Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use 
in animal nutrition. OJ L 268, 18.10.2003, p. 29. 
5   HuvePharma NV, Uitbreidingstraat 80, 2600 Antwerp, Belgium. 
6   EFSA Dossier reference: FAD-2010-0001. 
7  Commission  Regulation  (EC)  No  2148/2004  of  16  December  2004  concerning  the  permanent  and  provisional 
authorisations of certain additives and the authorisation of New uses of an additive already authorised in feedingstuffs. OJ 
L 370, 17.12.2004, p. 24. 
8  Commission Regulation (EC) No 828/2007 of 13 July 2007 concerning the permanent and provisional authorisation of 
certain additives in feedingstuffs. OJ L 184, 14.7.2007, p. 12. 
9  Commission Regulation (EC) No 322/2009 of 20 April 2009 concerning the permanent authorisation of certain additives in 
feedingstuffs. OJ L 101, 21.4.2009, p. 9. Hostazym X for poultry, piglets and pigs for fattening 
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Table 1:   Description and conditions of use of the additive as proposed by the applicant  
Additive   endo-1,4-beta-xylanase 
Registration number/EC 
No/No (if appropriate)  E1617 
Category(-ies) of additive  Zootechnical additives 
Functional group(s) of additive  Digestibility enhancers - enzymes 
 
Description 
Composition, description  Chemical 
formula 
Purity criteria 
(if appropriate) 
Method of analysis 
(if appropriate) 
Endo-1,4-beta  xylanase  (IUB 
3.2.1.8)  
Hostazym X 6 000 liquid: 6000 
EPU/ml,  sorbitol,  propylene 
glycol, benzoate, water  
Hostazym  X  15  000  liquid: 
15 000  EPU/ml,  sorbitol, 
propylene  glycol,  benzoate, 
water  
Hostazym  X  6 000 
Microgranulate:  6000  EPU/g, 
pregelatinised  starch,  wheat 
meal  
Hostazym  X  30 000 
Microgranulate:  30 000  EPU/g, 
pregelatinised  starch,  wheat 
meal 
NA  NA  Spectrophotometric 
 
Trade name (if appropriate)  Hostazym 
Name of the holder of 
authorisation (if appropriate)  Huvepharma AD 
 
Conditions of use 
Species or 
category of animal 
Maximum 
Age 
Minimum content  Maximum content  Withdrawal 
period 
(if appropriate)  Units/kg of complete feedingstuffs 
Chickens for 
fattening 
 
Turkeys for 
fattening 
 
Laying hens 
 
 
Weaned piglets 
 
Fattening pigs 
 
Other birds for 
fattening and 
laying 
NA 
1500 EPU 
 
 
1050 EPU 
 
 
1050 EPU 
 
 
1500 EPU 
 
1500 EPU 
 
 
1050 EPU 
 
NA  NA Hostazym X for poultry, piglets and pigs for fattening 
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Other provisions and additional requirements for the labelling 
Specific conditions or restrictions for 
use (if appropriate) 
Recommended dose range: 
Chickens for fattening: 1500 – 3000 EPU/kg feed 
Turkeys for fattening: 1050 – 2100 EPU/kg feed 
Laying hens; 1050 – 3000 EPU/kg feed 
Weaned piglets: 1500 – 3000 EPU/kg feed 
Fattening pigs: 1500 – 3000 EPU/kg feed 
Other birds for fattening and laying: 1050 – 3000 EPU/kg feed 
Specific conditions or restrictions for 
handling (if appropriate)  NA 
Post-market monitoring  
(if appropriate)  NA 
Specific conditions for use in 
complementary feedingstuffs  
(if appropriate) 
NA 
 
Maximum Residue Limit (MRL) (if appropriate) 
Marker residue  Species or category of 
animal 
Target tissue(s) or 
food products 
Maximum content in 
tissues 
NA  NA  NA  NA Hostazym X for poultry, piglets and pigs for fattening 
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ASSESSMENT 
1.  Introduction 
The additive Hostazym X is a preparation of endo-1,4-beta-xylanase (xylanase; EC 3.2.1.8) produced 
by  a  non-genetically  modified  strain  of  Trichoderma  citrinoviride  Bisset  (IM  SD135)  formerly 
identified  as  Trichoderma  longibrachiatum.  A  liquid  and  a  solid  formulation  of  this  product  are 
currently authorised as a feed additive for chickens for fattening, turkeys for fattening, laying hens and 
piglets  (weaned).  The  applicant  requested  the  additive  to  be  re-evaluated  when  used  in  these 
species/categories and  its use in feed to be extended to poultry for fattening or laying and pigs for 
fattening. Hostazym X is proposed to be classified as a zootechnical additive, functional group of 
digestibility enhancers. 
2.  Characterisation  
2.1.  Characterisation of the additive 
The additive is available in two solid and two liquid formulations. The enzymatic activity of xylanase 
is expressed in endo-pentosanase units (EPU). According to the applicant, 1 EPU is the amount of 
enzyme which releases 0.0083 μmol of reducing sugars (xylose equivalent) per minute from oat spelt 
xylan at pH 4.7 and 50 °C.  
The solid formulations, Hostazym X 6000 MicroGranulate and Hostazym X 30000 MicroGranulate, 
contain up to 3.3 % purified fermentation product, ~ 0.68 % pre-gelatinised starch and wheat meal (up 
to 100 %).
10 Hostazym X 6000 MicroGranulate ensures a minimum enzyme activity of 6 000 EPU/g 
and Hostazym X 30000 MicroGranulate of 30  000 EPU/g product.  Analysis of the batch-to-batch 
variation (five batches) showed a mean xylanase content of 6 340 EPU/g (4 % coefficient of variation 
(CV)) and 34 006 EPU/g  (10 % CV) in Hostazym X 6000 and  Hostazym X 30000, respectively.
11 
Analysis of the particle size distribution of Hostazym X 6000 and Hostazym X 30000 (three batches 
each) showed that 98.1 and 98.3 % of particles are bigger than 100 µm (the distribution below 100 µm 
was not provided). The dusting potential, as measured using a modification of the Stauber–Heubach 
test, was 0 (g per m
3) for both formulations.
12  
The liquid formulations, Hostazym X 6000 liquid and Hostazym X 15000 liquid, contain up to 1.7 % 
(w/w) purified fermentation product, up to  54 % sorbitol, ~ 11 % propylene glycol, < 0.3 % sodium 
benzoate and potassium s orbate and water (up to 100  %).
13  Hostazym X 6000 liquid   contains  a 
guaranteed enzyme activity of 6 000 EPU and Hostazym X 15000 liquid an enzyme activity of 15 000 
EPU/mL. A study of the  batch-to-batch variation (five batches) showed a mean  activity of 7 480 
EPU/mL (16 % CV) and 15 800 EPU/mL (4.6 % CV) for Hostazym X 6000 and 15000, respectively. 
The relative density of Hostazym X 6000 and 15000 liquid is 1.1 –1.3  g/mL.
14  The viscosity of 
Hostazym X 6000 liquid is 1.6 cP and of Hostazym X 15000 liquid is 3.6 cP.
15 
The applicant provided the results of studies verifying the absence of antibiotic activity (one batch) in 
the enzyme concentrate.
16 Microbial contamination (total coliforms, Escherichia coli and Salmonella) 
and heavy metals and arsenic, measured in at least three batches of the concentrate, were found to 
comply with JECFA specifications for food enzymes (JECFA, 2006).
17 Mycotoxins (aflatoxin B1, B2, 
G1, G2, ochratoxin A, sterigmatocystin, zearalenone, T-2 toxin) were also measured and found to be 
                                                       
10 Technical dossier/Section II/Annexes II.21 and II.33. 
11   Technical dossier/Section II/Annexes II.05 and II.06 and supplementary information October 2011/Annex 1. 
12 Technical dossier/Section II/Annexes II.12, II.13, II.14 and II.15. 
13 Technical dossier/Section II/Annexes II.22 and II.33. 
14 Technical dossier/Section II/Annexes II.07 and II.08 and supplementary information October 2011/Annex 1. 
15   Technical dossier/Supplementary information October 2011/Annexes 2 and 3. 
16 Technical dossier/Section II/Annex II.35. 
17 Technical dossier/Section II/Annex II.09. Hostazym X for poultry, piglets and pigs for fattening 
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below  the  limit  of  detection  (three  batches;  0.5  ppb  for  aflatoxins  and  ochratoxin,  20  ppb  for 
sterigmatocystin and 50 ppb for zearalenone and T-2 toxin).
18 The final formulations were analysed 
(one batch each) for the content of  lead (< 1 mg/kg), cadmium (< 0.1 mg/kg), mercury (< 1 mg/kg), 
arsenic  (< 0.1 mg/kg),  aflatoxin  B1  (< 0.5 µg/kg),  ochratoxin  A  (< 0.6 µg/kg),  deoxynivalenol 
(< 70 µg/kg) and zearalenone ( < 5 µg/kg).  Analysis of three batches of  each  formulation showed 
absence of Salmonella spp.
19 
2.2.  Manufacturing process 
The  current  authorisation  of  the  product  states  that  the  xylanase  is  obtained  from  a  strain  of 
Trichoderma longibrachiatum deposited at the International Mycological Institute with the accession 
number  SD  135.
20  During the current assessment ,  and  upon request,  the applicant  provided  the 
identification of the strain by molecular techniques. The results showed that the strain should now be 
classified as Trichoderma citrinoviride Bisset.
21 The enzyme contained in the product is obtained by 
fermentation of this strain, which has not been genetically modified. The xylanase is recovered from 
the fermentation broth and the (solid) concentrate is used to prepare the solid and liquid formulations. 
2.3.  Physico-chemical and technological properties of the additive 
2.3.1.  Shelf-life of the additive 
The shelf-life of all formulations of the additive was measured in three batches.  
In the case of the solid forms (Hostazym X 6000 and 30000 MicroGranular), samples were kept in 
bags at 25 °C/60 % relative humidity (RH) (Hostazym X 6000) and 30 °C/65 % RH (Hostazym X 
30000) for 24 months or at 40°C/75 % RH for six months. The mean initial values were 6 890 EPU/g 
and 33 903, respectively. Mean recoveries were above 90 % after 24 months at 25 °C and above 79 % 
after six months at 40 °C, regardless of the formulation.
22 
Samples of the liquid forms (Hostazym X 6000 and 15000 Liquid) were kept in plastic bottles at 25 °C 
for 12 months or at 40 °C for six months. The mean initial values were 6  776 EPU/mL and 16 770, 
respectively. Mean recoveries were above 88 % after 12 months at  25 °C and above 79 % after six 
months at 40 °C, regardless of the formulation.
23 
2.3.2.  Stability of the additive in premixtures 
The stability of the formulation Hostazym X 30000 MicroGranular, when added to vitamin mineral 
premixture (containing choline chloride) at an intended dose of 300 000 EPU/kg premixture, was 
studied in three batches.
24 Samples of the mixture were kept at 25  °C or 35 °C for up to six months. 
Mean recovery was 93 % and 80 % at 25 and 35 °C, respectively. 
2.3.3.  Stability of the additive in complete feed 
The stability of Hostazym X 30000 was studied when added to a complete feed for chickens for 
fattening (three batches of the formulation) or for fattening pigs (one batch).
 25 Two different enzyme 
activities were tested (1 500 and 3 000 EPU/kg feed) and the study included the effect of pelleting and 
the effect of storage (mash and pelleted feed). The mash feed was pelleted, reaching temperatures of 
65–75 °C; recoveries were above 90 % of the initial enzyme activity in all cases. The stability of the 
enzyme in mash and pelleted feed was studied at two different temperatures (25 and 35 °C) for three 
months. After three months‟ storage, mean recovery values in feed, regardless of the supplementation 
                                                       
18 Technical dossier/Section II/Annex II.34. 
19 Technical dossier/Section II/Annexes II.10 and II.11. 
20 Technical dossier/Section II/Annex II.19 and supplementary information December 2012/Annex 2. 
21   Technical dossier/Supplementary information January 2012/Annex 1. 
22   Technical dossier/Supplementary information October 2011/Annexes 4 and 5. 
23 Technical dossier/Supplementary information October 2011/Annexes 6 and 7. 
24 Technical dossier/Section II/Annex II.32 and Supplementary information October 2011/Annex 8. 
25 Technical dossier/Section II/Annex II.25 and Supplementary information October 2011/Annexes 9 and 10. Hostazym X for poultry, piglets and pigs for fattening 
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level and form (mash or pelleted), were above 90 % when the samples were kept at 25 °C and above 
80 % when samples were kept at 35 °C.
26  
The stability of Hostazym X 15000 Liquid (three batches) when added to a complete feed for chickens 
for fattening at 1 500 EPU/kg feed was studied.
27 The additive was added to mash and to pelleted feed. 
The stability was studied  following storage  at two different temperatures (25 and 35  °C) for three 
months. Mean recovery values  from mash and pelleted feed were above 82 and 90 %, respectively, 
when kept at 25 °C, and above 71 and 83 %, respectively, when kept at 35 °C.  
2.3.4.  Homogeneity   
From the above samples of premixtures and feed (mash and pelleted), 10 subsamples were evaluated 
in order to study the capacity of the additive (xylanase) to homogeneously distribute. The CV of the 
xylanase content in premixtures (solid formulation, three samples) ranged between 7.4 and 9.4 %. The 
CV of xylanase content in mash and pelleted feed ranged between 7.0–14.3 % (16 measurements) for 
the solid formulation and from 5.8 to 11.4 % (six measurements) for the liquid. Mash and pelleted 
samples showed similar ranges. 
2.4.  Conditions of use 
The  additive  is  to  be  used  in  feed  rich  in  non-starch  polysaccharides  at  a  minimum  dose  of 
1 500 EPU/kg  feed  for  chickens  for  fattening,  piglets  (weaned)  and  pigs  for  fattening  and  at  a 
minimum  dose  of  1 050  EPU/kg  feed  for  turkeys  for  fattening,  laying  hens  and  other  laying  or 
growing birds. The maximum recommended dose is 3 000 EPU/kg feed for all species, except for 
turkeys, for which it is 2 100 EPU/kg feed. 
2.5.  Evaluation of the analytical methods by the European Union Reference Laboratory 
(EURL) 
EFSA has verified the EURL report as it relates to the methods used for the control of the active 
substance in animal feed. The Executive Summary of the EURL report can be found in the Appendix. 
3.  Safety 
3.1.  Toxicological studies 
The test item used in the tests under this section (here below named Hostazym X) is the enzyme 
concentrate used in the manufacture of the additive Hostazym X.
28 
3.1.1.  Genotoxicity studies including mutagenicity  
3.1.1.1.  Bacterial reverse mutation assay 
Hostazym X dissolved in water was examined for mutagenic activity in Salmonella Typhimurium, 
strains  TA98,  TA100,  TA1535,  TA1537  and  TA1538,  in  the  presence  and  absence  of  metabolic 
activation (S9-mix from the liver of Aroclor 1254-induced rat).
29 The maximum concentration used 
was 10 mg/mL. The study was conducted in compliance with OECD  Guideline  471  (1983). The 
strains were exposed to the test material prior to plating (“treat and plate assay”). There was no 
evidence of toxicity and only in a single isolated case (not reproducible, nor dose response) was an 
increase in revertants observed. The positive controls acted as expected.  
                                                       
26   Percentage considering the initial enzyme activity in mash or pelleted feed. 
27 Technical dossier/Supplementary information October 2011/Annex 11. 
28 Technical dossier/Supplementary information November 2012. 
29 Technical dossier/Section III/Annex III 3.2.2.d and Supplementary information October 2011/Annex 16. Hostazym X for poultry, piglets and pigs for fattening 
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3.1.1.2.  Chromosome aberration test 
Hostazym X was tested in a chromosomal aberration assay using Chinese hamster ovary cells as the 
test system.
30 The test was conducted in the presence and absence of Aroclor 1254 -induced rat liver 
preparation cofactors (S9 mix) according to the OECD  Guideline  473 (1983) up to a maximu m 
concentration of 5 000 μg/mL. Because of excessive cytotoxicity, it was not possible to analyse the 
metaphases at concentrations above 313 and 2 500 μg/mL, with and without S9 mix, respectively. The 
test item induced structural chromosomal aberrations only in the absence of S9 mix at 1 250 and 
2 500 μg/mL.  Some  cytotoxicity  was  observed  at  genotoxic  concentrations  (95–30 %  survival, 
measured as cell count). 
3.1.1.3.  In vivo micronucleus test  
An in vivo genotoxicity test was conducted according to OECD 474 (1997).
31 Ten male and female 
rats were given  Hostazym X concentrate at  100, 500 or 2 000 mg/kg body weight (bw) by gavage 
(single dose). A positive and negative control group were also  included. Bone marrow cells were 
harvested after 24 or 48 hours. There was no increase in the number of micronucleated polychromatic 
erythrocytes in any of the test groups, while the positive control performed as expected; thus, the test 
item was not clastogenic in this test. However, there was no evidence for local toxicity at the level of 
bone marrow (alteration of polychromatic erythrocyte–normochromatic erythrocyte ratio). 
3.1.1.4.  In vivo comet assay 
An in vivo comet assay, provided upon request, was designed to assess the potential of Hostazym X 
concentrate to induce DNA strand breaks in the duodenum and the glandular stomach of Crl: CD(SD) 
rats.
32 Three parameters were evaluated: per cent  tail intensity, tail length (μm) and tail moment. 
The animals were treated with Hostazym X concentrate orally by gavage on two occasions, the second 
dose being administered approximately 21 hours after the first dose and three hours before sampling. 
On the basis of results from the preliminary toxicity test, dose levels of 500, 1 000 and 2 000 mg/kg 
per day were selected for the initial comet test. As no substantial differences in toxicity were observed 
between the sexes, the comet test was performed using male animals only. 
In the first experiment conducted at 500, 1 000 and 2 000 mg/kg bw per day, the slides of the two 
upper  doses  could  not  be  analysed  because  of  excessive  cytotoxicity  (i.e.  „hedgehog‟  or  „ghost‟ 
comets).  For  this  reason,  the  test  was  deemed  invalid  and  no  statistical  analysis  was  performed. 
However, at a dose of 500 mg/kg bw per day significant increases in all the analysed parameters were 
observed in the glandular stomach, but not in the duodenum. 
In the second experiment (125, 250 and 500 mg/kg bw per day), statistically significant increases in 
the per cent tail intensity were observed in the duodenum from a dose of 125 mg/kg bw per day and 
tail moment was increased at a dose of 250 mg/kg bw per day, while in the glandular stomach all the 
parameters were significantly increased at all doses. 
A third experiment was conducted with a further decreased dosage (12.5, 25, 50 and 125 mg/kg bw 
per  day).  In  the  duodenum  statistically  significant increases in the  per  cent  tail  intensity  and tail 
moment  were  observed  from  dose  50 mg/kg  bw  per  day,  while  in  the  glandular  stomach  all  the 
parameters were significantly increased from dose 25 mg/kg bw per day. 
In all experiments the significant induction of DNA strand breaks was associated with concomitant 
cytotoxicity, reflected by the presence of „hedgehog‟ or „ghost‟ comets.  
                                                       
30 Technical dossier/Section III/Annex III.3.2.2.e and Supplementary information October 2011/Annex 17. 
31 Technical dossier/Supplementary information October 2011/Annex 19. 
32 Technical dossier/Supplementary information November 2012/Annexes 2 and 3. Hostazym X for poultry, piglets and pigs for fattening 
 
EFSA Journal 2013;11(2):3105  11 
3.1.1.5.  Conclusions on genotoxicity 
Hostazym X was negative in a bacterial reverse mutation assay. Induction of chromosomal aberrations 
was observed in vitro only in the absence of metabolic activation and in the presence of slight to 
evident cytotoxicity. Negative results were reported in an in vivo micronucleus test in bone marrow, in 
which,  however,  no  evidence  of  target  exposure  was  reported.  Considering  that  hypothetical 
genotoxins  detected  in  vitro  are  expected  to  be  degraded  by  oxidative  metabolism,  the  in  vivo 
micronucleus  test  could  not  be  considered  conclusive.  An  in  vivo  comet  assay  using  oral 
administration demonstrated the induction of DNA breakage at the site of contact (glandular stomach 
and duodenum), in the presence of concomitant cytotoxicity. While a contribution of cytotoxicity to 
the observed induction of DNA breakage is possible, the presence in the fermentation product of 
genotoxic impurities cannot be excluded.  
3.1.2.  Subchronic oral toxicity study 
The  systemic  toxic  potential  of  Hostazym  X  to  Sprague–Dawley  rats  by  oral  administration  was 
assessed over a period of 13 weeks, in compliance with OECD Guideline 408 (1981).
33 Four groups, 
each comprising  10 male and  10 female Crl:CD(SD) rats, received the test material by gavage at 
dosages of 0, 100, 300, 1000 mg/kg bw per day in a total volume of 10 mL/kg bw. During the study, 
clinical  condition,  body   weight,  food  consumption,  water  consumption,  ophthalmoscopy, 
haematology, blood chemistry, organ weight, gross pathology and histopathology (control and high 
dose only) investigations were undertaken. 
No treatment-related effects on mortality, clinical signs, body weight, food and water consumption or 
ophthalmic parameters were found. There was a significant dose-related decrease in haemoglobin in 
males, a decrease in  alanine transaminase, an increase in globulin and increase in kidney weight 
(absolute only) in  males receiving the highest dose, and an increase in pituitary weight  in females 
receiving the two highest doses . There were no associated gross pathology findings, and histology  
revealed an increase in extramedullary haematopoiesis in four males in the highest dose group and 
mild testicular tubular atrophy in two males of the same group. No changes were seen in females. 
It is concluded that the observed changes were mild and not related to treatment. 
3.2.  Safety for the target species 
3.2.1.  Safety for chickens for fattening  
In a combined tolerance and efficacy trial, a total of 720 one-day-old male chicks (Ross 308) were 
distributed in 24 pens of 30 birds each and allocated to three dietary treatments (eight replicates per 
treatment) (see Table 2, trial 5).
34 The basal diets (starter, grower and finisher) based on wheat and 
soybean meal wer e supplemented with Hostazym  X (a solid formulation) to provide 0, 1  500 
(minimum recommended dose) and 300 000 (maximum recommended dose × 100) EPU/kg feed. The 
enzyme activities were confirmed by analysis. The feed was offered to the birds in mash form a nd ad 
libitum for 39 days. Feed consumption and body weight of the birds was measured biweekly. The data 
were subjected to analysis of variance (ANOVA) and a least significant difference (LSD) test was 
used to compare the means. 
Mortality was low (< 2 %) and not affected by the dietary treatments (see Table 3, trial 5). The mean 
final body weight of the birds was ~ 2.50 kg. Supplementation of the experimental diets with 100 
times the maximum recommended dose did not have negative effects on the performance of the birds.  
                                                       
33 Technical dossier/Section III/Annex III.3.1.1.b and supplementary information October 2011/Annex 18. 
34   Technical dossier/Supplementary information October 2011/Annex 12. Hostazym X for poultry, piglets and pigs for fattening 
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3.2.2.  Safety for turkeys for fattening  
In a combined tolerance and efficacy trial, a total of 1 080 one-day-old female chicks (Big 6) were 
distributed in 27 pens of 40 birds each and allocated to three dietary treatments (nine replicates per 
treatment) (Table 4, trial 3).
35 The basal diets (starter, grower and finisher) based on wheat (and rye) 
and soybean meal were supplemented with Hostazym X (a solid formulation) to provide 0, 1  050 
(minimum recommended dose)  or 210 000 (100 times the maximum recommended dose) EPU/kg 
feed. The enzyme activities were confirmed by analysis (100× was  321 000 EPU/kg feed). The feed 
was offered to the birds in mash form and ad libitum for 84 days. Feed consumption and body weight 
of the birds was measured throughout the study. The data were subjected to an ANOVA and the 
Newman–Keuls test was used to compare the means. 
Mortality was low (~ 2 %) and not affected by the dietary treatments. The mean final body weight of 
the birds was ~ 7.35 kg (see Table 5, trial 3). Supplementation of the experimental diets with 100 
times the maximum recommended dose did not have negative effects on the performance and health 
status of the birds. 
3.2.3.  Safety for laying hens 
In a tolerance trial, a total of 512 22-week-old Hy-Line hens were caged in groups of four hens and 
distributed to four dietary treatments (eight replicates per treatment).
36 A basal diet based on wheat, 
barley and soybean meal was supplemented with Hostazym X ( 30 000 solid) to provide 0, 1  050 
(minimum recommended dose), 1  500  or  300 000 (100  times the  maximum recommended dose) 
EPU/kg feed. Enzyme activities were confirmed by analysis. The dietary treatments were offered  ad 
libitum and in mash form for 168 days. Laying production of the hens was measured throughout the 
study. Data were subject to ANOVA and a LSD test was performed to compare the means. 
No hens died during the study and the laying rate was ~ 95 %. Supplementation of the experimental 
diets with 100 times the maximum recommended dose did not have negative effects on the hens or on 
their laying performance. 
3.2.4.  Safety for minor poultry species 
The mode of action of the xylanase is well known and can be reasonably considered to be similar 
among  the  different  poultry  species.  Therefore,  the  conclusions  on  the  tolerance  drawn  from  the 
studies provided in chickens and turkeys for fattening and laying hens can be extrapolated to all other 
poultry species for fattening and laying, provided that the same maximum dose applies. 
3.2.5.  Safety for piglets 
A combined tolerance and efficacy trial was conducted with a total of 180 weaned piglets (females and 
males, Landrace   Large White   Piétrain).
37 Pigs were distributed to three treatments according to 
weight and sex (30 pens of six pigs; sex separated).  The initial body weight of the piglets was 7.7 kg 
(28 days old). Two basal diets (phase 1 and phase 2) based on wheat, barley and soybean meal  were 
offered ad libitum for 42 days in mash form (phase 1 for 14 days and phase 2 for the 28 following 
days).  The  basal  diets  were  supplemented  with  Hostazym  X  (15000  liquid)  to  provide  0,  1 500 
(minimum  recommended  dose  level)  or  300 000  (100  times  the  maximum  recommended  dose) 
EPU/kg feed. Enzyme activities were confirmed by analysis. Zootechnical performance and mortality 
were monitored throughout the study. The statistical analysis used was the variance analysis; a Fisher 
test was used to compare group means. 
                                                       
35   Technical dossier/Supplementary information October 2011/Annex 13. 
36   Technical dossier/Supplementary information October 2011/Annex 15. 
37 Technical dossier/Supplementary information October 2011/Annex 14. Hostazym X for poultry, piglets and pigs for fattening 
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Three animals in the control group and two animals in the group receiving the 100-fold dose died from 
diarrhoea/starvation during the study. No significant differences (P > 0.05) between the treatment 
groups in feed intake (551, 555, 539 g/day), final body weight (20.5, 21.7, 21.0 kg), daily weight gain 
(299, 325, 307 g/day) and feed to gain ratio (1.85, 1.69, 1.76) were observed. Supplementation of the 
diet with 100 times the maximum recommended dose did not have negative effect on the performance 
of the piglets. 
3.2.6.  Safety for pigs for fattening 
No specific study was provided to demonstrate the tolerance of pigs for fattening. Given that weaned 
piglets is considered the most sensitive category in that species, the FEEDAP Panel considers that 
conclusions reached in piglets can be extended to pigs for fattening, provided that the same maximum 
dose applies. 
3.2.7.  Conclusions on the safety for the target species 
The solid and liquid forms of the additive are considered equivalent in terms of safety for the target 
species when used at the same dose.  
The tolerance studies provided in chickens and turkeys for fattening, laying hens and piglets showed 
that a dose 100 times the dose of 3 000 EPU/kg (300 000 EPU/kg feed) was well tolerated by the 
animals. No specific study was provided to demonstrate the tolerance of pigs for fattening. Since 
weaned piglets is considered the most sensitive category in that species, the FEEDAP Panel considers 
that conclusions reached in piglets can be extended to pigs for fattening, provided that the same 
maximum dose applies. Moreover, the conclusions from the studies provided in chickens and turkeys 
for fattening and laying hens can be extrapolated to all other minor poultry species for fattening and 
laying, provided that the same maximum dose (3 000 EPU/kg feed) applies. Although the tolerance 
studies did not indicate any adverse effects of the additive, considering the genotoxic hazard from the 
product, the FEEDAP Panel cannot conclude on the safety of the additive for the target species.  
3.3.  Safety for the consumer 
The results of an in vitro chromosomal aberration test and of an in vivo comet assay indicate the 
presence of genotoxic activity in the product (see Section 3.1). Since the identity of the substance 
causing this effect is unknown, the risk to the consumer cannot be established. The subchronic rat 
study did not indicate any additional concern for consumer safety arising from the use of Hostazym X 
as  a  feed additive.  Owing  to  lack  of  information  on  the  nature and  fate  of potentially  genotoxic 
material in food derived from animals receiving the additive, the FEEDAP Panel cannot conclude on 
the safety of the additive for the consumer. 
3.4.  Safety for the user  
No specific studies were provided. Therefore, the product should be considered a potential skin and 
eye irritant, and a potential skin and respiratory sensitiser.  
Persons handling the additive may be in direct contact with it. Therefore, the conclusions reached on 
the  genotoxicity  need  to  be  taken  into  account.  The  FEEDAP  Panel  considers  that  any  level  of 
exposure to the additive is hazardous. 
3.5.  Safety for the environment 
The active substance of Hostazym X (xylanase) is a protein and as such will be degraded/inactivated 
during the passage through the digestive tract of animals. Therefore, no risks to the environment are 
expected and no further environmental risk assessment is required. Hostazym X for poultry, piglets and pigs for fattening 
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4.  Efficacy 
4.1.  Efficacy for chickens for fattening 
Five  performance  trials  and  a  short-term  trial  were  considered.  Details  of  the  design  of  the  five 
performance trials are presented in Table 2 and the relevant results in Table 3. Trial 5 is the tolerance 
trial already described in Section 3.1.1. In the other four trials, the basal diets (based on wheat and 
soybean  meal)  were  supplemented  with  Hostazym  X  (solid  or  liquid  forms)  to  provide  0  or 
1 500 EPU/kg feed. Enzyme activities were confirmed by analysis (data not provided for trial 1). Trial 
2 followed a 2 × 2 experimental design with two levels of enzyme supplementation and two levels of 
flavomycin (0 or 4 mg); the statistical analysis revealed no interaction of the two factors. In trial 4, two 
different forms of the additive (solid or liquid) were tested at the same dose.  
The trials started when the birds were one day of age, with the exception of trial 1 (eight days), and the 
birds were under study for at least 35 days. Performance of the birds was measured throughout the 
experimental period and the data were subject to statistical analysis. 
Mortality was low (< 5 %) and not related to the experimental treatments. The supplementation of the 
basal diet with Hostazym X resulted in a higher daily weight gain in trials 1, 3 and 4 and a better feed 
to gain ratio in trials 2, 3, 4 and 5 (only the liquid formulation). 
Table 2:   Experimental design of the performance trials carried out in chickens for fattening 
Trial no 
(duration, 
days) 
Animal 
breed 
(age at start)
1 
Sex 
Total no of animals 
(animals/replicate) 
Replicates/treatment 
Diet 
composition 
(form) 
Feed enzyme activity (EPU/kg) 
Intended
2  Analysed
3 
1
38 
35 
Ross 
(eight days) 
♂ 
96 
(6) 
8 
Wheat, 
soybean meal 
(mash) 
0 
1 500  Not provided 
2
39 
42 
Hybro 
(one day) 
♂/♀ 
180 
(75) 
6 
Wheat, 
soybean meal 
(pelleted) 
0/0 
0/4 
1 500/0 
1 500/4 
– 
– 
2 265 
1 715 
3
40 
35 
Cobb 
(one day) 
♂/♀ 
1 120 
(40) 
14 
Wheat, 
soybean meal 
(mash) 
0 
1 500 
417 
1 531 
4
41 
36 
Ross 
(one day) 
♂ 
1 000 
(50) 
6 / 7 
Wheat, maize, 
soybean meal 
(mash, 
pelleted) 
0 
1 500 solid 
1 500 liquid 
320 
1 085 
2 475 
5
42 
39 
Ross 308 
(one day) 
♂ 
720 
(30) 
8 
Wheat, 
soybean meal 
(mash) 
0 
1 500 
300 000 
0 
1 574 
269 300 
1  In trial 1, during the first eight days the birds were offered the control diet. 
2  For trial 2, values indicate enzyme activity (EPU/kg feed)/flavomycin content (in mg). 
  For trials 2, 3 and 4, values are the mean of starter and grower/finisher diets; values for trial 5 are for three diets. 
 
The short-term trial was a balance trial performed with 15-day-old chickens.
43 The study lasted for 11 
days. There were a total of eight dietary treatments with five replicates each (cages of four birds). The 
first two dietary treatments were obtained from a basal diet (ingredient list not provided, but dietary 
composition provided) supplemented at 0 or 1 500 EPU/kg feed. The unsupplemented basal diet was 
                                                       
38 Technical dossier/Section IV/Annex IV.4.3.1.a. 
39 Technical dossier/Section IV/Annex IV.4.3.1.b. 
40 Technical dossier/Section IV/Annex IV.4.3.1.c. 
41 Technical dossier/Supplementary information October 2011/Annex 20. 
42 Technical dossier/Supplementary information October 2011/Annex 12. 
43 Technical dossier/Section IV/Annex IV.4.2.1.a. Hostazym X for poultry, piglets and pigs for fattening 
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used to obtain two more basal diets by replacing 30 % or a 60 % of the basal diet with wheat. These 
two basal diets with a high wheat content were supplemented at 0, 750 or 1 500 EPU/kg feed. The 
intended activities were confirmed by analysis. The balance study started when the birds were 22 days 
old and lasted for four days. Birds were offered the feed restrictively (95 %). Gross energy, nitrogen, 
fat and amino acids were measured in feed and in excreta. Data were subject to ANOVA followed by 
an LSD test to determine group differences. 
The results showed that Hostazym X at 1 500 EPU/kg feed significantly increased the metabolisable 
energy content (nitrogen corrected) of the feed containing 60 % wheat (from 11.77 to 12.08 MJ/kg 
feed). 
Table 3:   Effect of Hostazym X on the performance of chickens for fattening 
Trial no 
Treatment  Daily weight 
gain (g/day) 
Feed to gain 
ratio  Mortality (n/%)
1  Hostazym 
(EPU/kg)  
Flavomycin 
(mg/kg) 
1  0 
1 500 
 
 
49.0
b 
51.7
a 
1.91 
1.84 
1 
3 
2 
0 
0 
1 500 
1 500 
0 
4 
0 
4 
45.5 
46.7 
45.6 
46.7 
1.97
a 
1.95
a 
1.92
b 
1.88
b 
3.5 
3.3 
2.6 
3.3 
3  0 
1500 
  55.9
b 
57.0
a 
1.75
a 
1.73
b 
1.1 
1.1 
4 
0 
1 500 (granular) 
1 500 (liquid) 
 
51.9
b 
53.6
a 
54.5
a 
1.78
a 
1.76
a 
1.72
b 
3.9 
3.1 
3.6 
5 
0 
1 500 
300 000 
  62.3 
64.2 
63.9 
1.64
a 
1.61
b 
1.60
b 
0.4 
1.3 
1.7 
1 Figures are number of animals that died or were culled in trial 1 and mortality (%) in the other trials. 
a,b Values within one column for a given trial with a different superscript are significantly different (P < 0.05). 
4.2.  Efficacy for turkeys for fattening  
Three performance trials were considered. Details of the study design are provided in Table 4 and the 
summary of the relevant results in Table 5. In trials 1 and 2, the basal diets (starter, grower(s), finisher) 
were  supplemented  with Hostazym  X  (solid  forms)  to  provide  0  or  1 050  EPU/kg  feed.  Enzyme 
activities were confirmed by analysis. The birds were fed the dietary treatments for at least 84 days. 
The performance of the birds was measured throughout the experimental period and the data were 
subject to ANOVA followed by a mean comparison using the LSD. Trial 3 is the tolerance trial 
already described in Section 3.1.2. Hostazym X for poultry, piglets and pigs for fattening 
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Table 4:   Experimental design of the performance trials carried out in turkeys for fattening 
Trial no 
(duration, 
days) 
Animal breed 
(age at start) 
Sex 
Total no of animals 
(animals/replicate) 
Replicates/treatment 
Diet 
composition 
(form) 
Feed enzyme activity (EPU/kg)
1 
Intended  Analysed
2 
1
44  
(112) 
BUT 9 
(one day) 
♂ 
360 
(30) 
6 
Wheat, rye, 
soybean meal 
(mash/pellets) 
0 
1 050 
135 
1 240 
2
45 
(84)  
BUT 8 
(one day) 
♂ 
384 
(12) 
16  
Wheat, soybean 
meal 
(pellets) 
0 
1 050 
234 
1 383 
3
46 
(84)  
Big 6 
(one day) 
♀ 
1080 
(40) 
9 
Wheat, soybean 
meal 
 (crumb/pellets) 
0 
1 050 
210 000 
134 
1 353 
321 333 
1  In trials 2 and 3, three basal diets (starter, grower and finisher diets) were formulated according to the requirements of the   
birds; in trial 1, four diets were used. 
2  Mean values for four diets in trial 1 and for three diets in trials 2 and 3. 
 
Mortality was low (< 5 %) and not related to the dietary treatments. The use of Hostazym X at 1 050 
EPU/kg significantly increased body weight gain and feed to gain ratio in all three trials.  
Table 5:   Effect of Hostazym X on the performance of turkeys for fattening 
Trial no  Hostazym 
(EPU/kg feed) 
Final body 
weight (kg)
1 
Daily weight 
gain (g/day) 
Feed to gain 
ratio 
Mortality and 
culling 
(%) 
1  0 
1 050 
12.83
b 
13.11
a 
114
b 
117
a 
2.49
a 
2.42
b 
4.4 
4.4 
2  0 
1 050 
10.22
b 
10.40
a  Not provided  1.96
a 
1.92
b 
4.7 
3.6 
3 
0 
1 050 
210 000 
7.15
b 
7.42
a 
7.47
a 
84.5
b 
87.7
a 
88.7
a 
2.26
a 
2.19
b 
2.13
c 
2.2 
2.2 
1.9 
1  Values for trial 2 are total weight gain. 
a,bValues within one column for a given trial with a different superscript are significantly different (P < 0.05). 
4.3.  Efficacy for laying hens  
Four performance trials were considered; details of the study design are provided in Table 6 and the 
summary of the relevant results in Table 7. Basal diets were supplemented with Hostazym X (solid 
forms) to provide 0 or different enzyme dosages from 1 050 to 1 500 EPU/kg feed. Enzyme activities 
were confirmed by analysis. Trial 4 followed a 3 × 2 design with three levels of metabolisable energy 
and two levels of enzyme. The statistical analysis revealed no interaction between the two factors and 
therefore Table 7 shows the values for the enzyme effect. The hens were under study for at least 24 
weeks. The laying performance of the hens was measured throughout the experimental period and the 
data were subject to an ANOVA followed by different mean comparison tests.  
                                                       
44   Technical dossier/Section IV/Annex IV.4.3.5.b. 
45 Technical dossier/Supplementary information October 2011/Annex 21. 
46 Technical dossier/Supplementary information October 2011/Annex 13. Hostazym X for poultry, piglets and pigs for fattening 
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Table 6:   Experimental design of the performance trials carried out in laying hens 
Trial 
no 
Animal breed 
(age at start) 
Duration 
(weeks) 
Total no of animals 
(animals/replicate) 
Replicates/treatment
1 
Diet composition 
(form)
  
Feed enzyme activity (EPU/kg)
2 
Intended  Analysed
3 
1
47  
Unspecified 
20 weeks 
48 
432 
(18) 
8 
Wheat, rye, barley, 
soybean meal 
(mash) 
0 
1 050 
1 500 
392
  
1 303
  
1 823
  
2
48  
Hy-Line  
20 weeks 
26 
444  
(2) 
74 
Wheat, triticale, 
rye, soybean meal 
(mash) 
0 
1 050 
1 200 
853 
2 020 
2 085 
3
49  
Hy-Line Brown 
18 weeks 
24 
180 
(3) 
20  
Wheat, barley, 
soybean meal 
(mash) 
0 
1 050 
1 500 
225 
1 317 
 
1 740  
4
50 
Hy-Line W-36 
18 weeks 
24 
432 
(9) 
8 
Maize, soya bean 
meal 
(mash) 
0 
1 050 
50/72/55 
1 043/990/1 127 
1  In trial 1 the replicate was a group of six cages with three hens each (total of 18 hens per replicate). 
2  Trial 4 was a 3   2 factorial design with three levels of energy in the diets and two supplementation levels for the enzyme. 
3  Mean values from six samples in trial 1, from two diets in trial 2 and from three in trial 3. Values in trial 4 represent the 
three diets with different metabolisable energy content. 
 
Mortality in the experiments was within the normal ranges, being greatest in trial 1 (~ 6.5 %), and not 
related to treatments. The results showed that the supplementation of the diets with Hostazym X 
permitted to reach a higher egg mass production when added at 1 500 EPU/kg feed in trial 1 and 4, 
and at the same dose in trial 3, a higher egg weight was found. In trial 2, supplementation with 1 050 
EPU/kg resulted in an improvement of the feed to egg ratio and egg mass production but the effect 
was lost at the dose of 1 200 EPU/kg. 
Table 7:   Effect of Hostazym X on the performance of laying hens 
Trial no  Hostazym 
(EPU/kg feed) 
Laying rate
1  Egg weight (g)  Egg mass 
production
2 
Feed to egg ratio 
(g/g) 
Mortality 
(n/%)
3 
1 
0 
1 050 
1 500 
90.8 
91.9 
92.1 
61.6 
61.9 
62.2 
55.9
b 
56.9
ab 
57.3
a 
2.00 
1.97 
1.97 
8.8 
4.7 
5.6 
2 
0 
1 050 
1 200 
165 
166 
165 
64.2 
65.1 
64.2 
10.6
b 
10.8
a 
10.6
b 
2.15
a 
2.06
b 
2.14
a 
2 
6 
2 
3 
0 
1 050 
1 500 
152 
151 
152 
57.6
b 
57.8
b 
59.4
a 
8.73 
8.71 
9.02 
2.10 
2.11 
2.09 
 
4  0 
1 050 
87.8
b 
89.7
a 
58.5 
58.8 
53.8
b 
55.5
a 
1.92
a 
1.86
b 
3 
2 
1  Laying rate as percentage in trials 1 and 4, and as total number of eggs per hen in trials 2 and 3. 
2  Egg mass production expressed as g/day per hen in trials 1 and 4 and as total egg mass per hen (in kg) in trials 2 and 3. 
3  Mortality as percentage in trial 1 and as total number of hens in the other trials. In trial 3 only one hen died, but the dietary 
group was not specified. 
a,bValues within one column for a given trial with a different superscript are significantly different (P < 0.05). 
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4.4.  Efficacy for weaned piglets  
Three long-term efficacy trials were considered. Details on the experimental design are presented in 
Table 8 and the performance results are shown in Table 9. 
In the three trials, the diets were supplemented with Hostazym X (solid in trial 1 and 3 and liquid in 
trial 2) at 0 or 1 500 EPU/kg feed (enzyme activities confirmed by analysis). Diets were offered ad 
libitum,  as  pre-starter  (0–14  days)  and  starter  (14–42  days).  The  statistical  analysis  of  the  data 
considered the pen as the experimental unit (except for body weight and average daily gain in trial 2).  
Table 8:   Experimental design of the performance trials carried out in weaned piglets 
 Trial no 
(duration, 
days) 
Animal breed 
(age at start) 
Sex
1 
Total no of animals 
(animals/replicate) 
Replicates/treatment 
Diet composition 
(form)
  
Feed enzyme activity (EPU/kg) 
Intended  Analysed
2 
1
51 
(42) 
Fomeva 
(25 days) 
♀/♂c (separated) 
144 
(4) 
18 
Wheat, barley, 
soybean meal (pellets) 
0 
1 500 
540/250 
2 210/1 860 
2
52  
(42) 
Landrace × Large 
White   Piétrain 
(28 days) 
♀/♂ (separated) 
120  
(6) 
10 
Wheat, barley, fish 
meal, whey, soybean 
meal 
(mash) 
0 
1 500 
137/259 
1 590/1 720 
3
53  
(42) 
Large White × 
Landrace 
(33 days) 
♂ 
128 
(4) 
16  
Cooked wheat, 
porridge oats, full fat 
soya, whey, fishmeal 
(pellets) 
0 
1 500 
195/310 
1 470/1 450 
1  ♂c, castrated males. 
2  Analysed enzyme activity in pre-starter/starter diets.  
 
In the first trial, three piglets in the treatment group died and the necropsy revealed pneumonia as the 
most  likely  cause  of  death.  In  the  second  trial,  three  animals  from  the  control  group  died  from 
diarrhoea/starvation. In the third trial there were no deaths throughout the entire period of the study. 
Significant positive effects of Hostazym X on final body weight were noted in trial 1, on weight gain 
in trials 1 (daily) and 3 (total) and on feed to gain ratio in all three trials. 
Table 9:   Effect of Hostazym X on the performance of weaned piglets 
Trial no  Hostazym 
(EPU/kg feed) 
Initial body 
weight (kg) 
Final body 
weight (kg)
1  Weight gain
2  Feed to gain 
ratio 
Mortality 
(n/total) 
1  0 
1 500 
6.8 
6.8 
22.54
b 
24.43
a 
375
b 
411
a 
1.93
a 
1.77
b 
0/72 
3/72 
2  0 
1 500 
7.7 
7.7 
20.5 
21.7 
299 
325 
1.85
a 
1.70
b 
3/60 
0/60 
3  0 
1 500 
9.5 
9.5 
28.9 
29.2 
19.4
a 
19.7
b 
1.70
a 
1.68
b 
0/64 
0/64 
1  Final body weight values for trial 3 are calculated values. 
2  Daily body weight gain for trials 1 and 2 (g/day) and total weight gain for trial 3 (kg). 
a,b Values within one column for a given trial with a different superscript are significantly different (P < 0.05). 
4.5.  Efficacy for pigs for fattening  
Five long-term trials were considered. The experimental design is shown in Table 10 and relevant 
results are presented in Table 11. 
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Table 10:   Experimental design of the performance trials carried out in pigs for fattening 
Trial no 
(duration, 
days) 
Animal breed 
(initial body weight) 
Sex 
Total no of animals 
(animals/replicate) 
Replicates/treatment 
Diet composition 
(form) 
Feed enzyme activity 
(EPU/kg) 
Intended  Analysed
2 
1
54  
85 
Commercial hybrid 
(31 kg) 
♀/♂c (mixed) 
300 
(20) 
5 
Wheat, barley, rye, 
soybean meal, 
rapeseed meal 
(pellets) 
0 
1 050 
1 500 
150 
1 280 
1 720 
2
55 
85 
Commercial hybrid 
(31 kg) 
♀/♂c (mixed) 
400  
(20) 
5 
Triticale, barley, 
soybean meal, 
rapeseed meal 
(pellets) 
0 
1 050 
1 500 
150 000 
0/15 
1 120/1 190 
1850/1 760 
146 500/154 300 
3
56 
74 
Landrace   Large 
White   Piétrain 
(34 kg) 
♀/♂c (mixed) 
517 
(11 to 14) 
20  
Wheat, soybean 
meal, sunflower 
meal, rapeseed 
meal 
(mash) 
0 
1 500 
210/150 
1 610/1 470 
4
57 
74 
Landrace   Large 
White   Piétrain 
(37 kg) 
♀/♂c (mixed) 
574 
(14 to 15) 
20 
Barley, wheat, 
soybean meal 
(mash) 
0 
1 500 
170/222 
1 518/1 590 
5
58 
76 
Landrace   Large 
White   Piétrain 
(30 kg) 
♀/♂c (mixed) 
408 
(13 to 16) 
14 
Wheat, barley, 
soya bean meal, 
rapeseed meal 
(mash) 
0 
1 500 
190/245 
1 625/1 510 
1  ♂c, castrated males. 
2  Analysed enzyme activity in grower/finisher diets; otherwise not specified. 
 
In  all  trials, the  diets  were  offered  ad libitum,  as  grower and finisher  diet. The  basal diets  were 
supplemented with Hostazym X to provide 0 or different dosages of xylanase (1 050, 1 500, 150 000 
EPU/kg feed), the enzyme activities were confirmed by analysis. A solid formulation of the additive 
was used in trials 1 and 2 while a liquid was used in trials 3 to 5. The study duration ranged between 
74 to 85 days. ANOVA was carried out with the data obtained using the pen as the experimental unit.  
Mortality was low and not treatment related. Hostazym X significantly improved performance of pigs 
at 1 050 EPU/kg in trials 1 and 2 and at 1 500 EPU/kg feed in all five trials. 
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Table 11:   Effect of Hostazym X on the performance of pigs for fattening 
Trial no  Hostazym 
(EPU/kg feed) 
Initial body 
weight (kg) 
Final body 
weight (kg) 
Daily weight 
gain (g/day) 
Feed to 
gain ratio 
Dead and culled 
(n/total n) 
1 
0 
1 050 
1 500 
31.0 
31.0 
31.0 
110
b 
113
a 
113
a 
931
b 
962
a 
968
a 
3.00
a 
2.82
b 
2.80
b 
0/100 
0/100 
0/100 
2 
0 
1 050 
1 500 
150 000 
31.0 
31.0 
31.0 
31.0 
107
b 
109
a 
109
a 
109
a 
887
b 
910
a 
914
a 
908
a 
2.86 
2.80 
2.78 
2.76 
0/100 
0/100 
0/100 
0/100 
3  0 
1 500 
34.3 
34.2 
92.6 
93.0 
783 
787 
2.99
a 
2.89
b 
14/260 
18/257 
4  0 
1 500 
37.5 
37.4 
93.0 
93.6 
742 
750 
3.05
a 
2.94
b 
13/288 
9/286 
5  0 
1 500 
30.2 
30.2 
86.1 
88.4 
726 
758 
2.83
a 
2.72
b 
5/202 
8/206 
a,bValues within one column for a given trial with a different superscript are significantly different (P < 0.05). 
4.6.  Conclusions on the efficacy on the target species 
Solid and liquid forms of the additive are considered equivalent in terms of efficacy.  
Based on the results obtained in the efficacy studies, the FEEDAP Panel concludes that Hostazym X 
has the potential to be efficacious in turkeys for fattening at the dose of 1 050 EPU/kg feed and in 
chickens  for  fattening,  laying  hens,  piglets  (weaned)  and  pigs  for  fattening  at  the  dose  of 
1 500 EPU/kg feed. 
The mode of action of the xylanase is well known and can be reasonably considered to be similar in 
the  different  poultry  species.  Therefore,  the  conclusions  on  the  efficacy  drawn  from  the  studies 
provided can be extrapolated to all other poultry species for fattening and laying. The dose that is 
considered efficacious in minor growing poultry species is 1 050 EPU/kg
59 feed and in minor laying 
poultry species is 1 500 EPU/kg feed. 
5.  Post-market monitoring 
The  FEEDAP  Panel  considers  that  there  is  no  need  for  specific  requirements  for  a  post-market 
monitoring  plan  other  than  those  established  in  the  Feed  Hygiene  Regulation
60  and  Good 
Manufacturing Practice. 
CONCLUSIONS  
The fermentation product that is used to prepare the additive showed negative results in a bacterial 
reverse mutation assay. However, the results of an in vitro chromosomal aberration test and of an in 
vivo  comet  assay  indicate  the  presence  of  genotoxic  activity.  Since  the  identity  and  fate  of  the 
substance causing this effect is unknown, the risk to the target species, consumers and users cannot be 
identified.  
The tolerance studies provided in chickens and turkeys for fattening, laying hens and piglets showed 
that a dose 100 times the dose of 3 000 EPU/kg was well tolerated by the animals. The FEEDAP Panel 
considers that conclusions reached in the major poultry species can be extrapolated to minor poultry 
species provided that the same maximum dose applies (3 000 EPU/kg feed). Similarly, the conclusions 
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reached in piglets can be extended to pigs for fattening at the same maximum dose. Although the 
tolerance studies did not indicate any adverse effects of the additive, the FEEDAP Panel, considering 
the genotoxic hazard from the product, cannot conclude on the safety for the target species. 
Although the results obtained in a subchronic rat study did not indicate any concerns for consumer 
safety arising from the use of Hostazym X as a feed additive, owing to the genotoxic activity present 
in the product, the FEEDAP Panel cannot conclude on the safety for the consumer. 
No specific studies to address the safety for the user were provided by the applicant; consequently, the 
additive should be considered a potential skin and eye irritant, and a potential skin and respiratory 
sensitiser. Persons handling the additive may be in direct contact with it. Therefore, the conclusions 
reached regarding the genotoxicity need to be taken into account. The FEEDAP Panel considers that 
any level of exposure to the additive is hazardous. 
The active substance of Hostazym X (xylanase) is a protein and as such will be degraded/inactivated 
during the passage through the digestive tract of animals. Therefore, no risks to the environment are 
expected.  
Based on the results obtained in the efficacy studies, the FEEDAP Panel concludes that the additive 
has the potential to be efficacious in turkeys for fattening at the dose of 1 050 EPU/kg feed and in 
chickens  for  fattening,  laying  hens,  piglets  (weaned)  and  pigs  for  fattening  at  the  dose  of  1 500 
EPU/kg feed. The FEEDAP Panel considers that the conclusions on the efficacy drawn from the 
studies provided in major poultry species can be extrapolated to all other minor poultry species for 
fattening and laying. The dose that is considered efficacious in minor growing poultry species is 1 050 
EPU/kg feed and in minor laying poultry species is 1 500 EPU/kg feed .  
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APPENDIX 
Executive Summary of the Evaluation Report of the European Union Reference Laboratory for 
Feed Additives on the Method(s) of Analysis for Hostazym X
61 
In the current application authorisation is sought for Hostazym X under article 4(1) and article 10(2) 
for  Hostazym  X  under  the  category  "zootechnical  additives",  functional  groups  4(a)  "digestibility 
enhancers", according to Annex I of Regulation (EC) No 1831/2003. The authorisation for chickens 
for fattening, turkeys for fattening, laying hens, weaned piglets, pigs for fattening and other birds for 
fattening  or  laying  is  requested.  Hostazym  X  contains  endo-1,4- -xylanase  (EC  3.2.1.8)  as  active 
agent, produced by the strains of Trichoderma longibrachiatum (IMI 356040). This feed additive is 
already authorised with the number E 1617 by the Commission Regulations (EC) 2148/2004, (EC) 
828/2007 and (EC) 322/2009. 
The  enzymatic  activity  of  endo-1,4- -xylanase  is  expressed  in  endo-pentosanase  units  (EPU). 
According to the applicant, one EPU is the amount of enzyme which releases 0.0083 μmol of reducing 
sugars (xylose equivalent) per minute from oat spelt xylan at pH 4.7 and 50 °C.  
The product is intended to be marketed as solid (Hostazym X Microgranulate) and liquid (Hostazym X 
Liquid)  formulations  used  in  compound  feed  rich  in  non-starch  polysaccharides  (mainly 
arabinoxylans). Two solid formulations have a guaranteed minimum activity of endo-1,4- -xylanase 
of 6000 and 30000 EPU/g. Two liquid formulations have a guaranteed minimum activity of endo-1,4-
-xylanase of 6000 and 15000 EPU/g. Hostazym X is intended to be mixed into premixtures and/or 
complete feedingstuffs: to obtain minimum activities of endo-1,4- -xylanase in feedingstuffs of: 
-  1050 EPU/kg for turkeys for fattening, laying hens and other birds for fattening or laying, and  
-  1500 EPU/kg for chickens for fattening, weaned piglets and pigs for fattening. 
For the determination of the activity of endo-1,4- -xylanase in the feed additive, premixtures and 
feedingstuffs, the applicant proposes a single laboratory validated and further verified colorimetric 
methods based on the quantification of water soluble dyed fragments produced by the action of endo-
1,4  -xylanase  on  commercially  available  azurine  cross-linked  wheat  arabinoxylan  substrates. 
Enzymatic activity of the sample is calculated using a reference enzyme standard, available from the 
applicant  upon  request.  The  following  method  performance  characteristics  were  derived  from  the 
validation and verification studies:  
for the feed additive: - a relative standard deviation for repeatability (RSDr) ranging from 1.9 to 3.3 %; 
-  a  relative  standard  deviation  for  intermediate  precision  (RSDint)  ranging  from  1.9  to 
3.3 %; and - a recovery rate (RRec) ranging from 101 to 104 %; 
for premixtures: - RSDr ranging from 3.2 to 8.2 %; - RSDint = 3.2 %, and - RRec ranging from 96 to 
103 %; 
for feedingstuffs: - RSDr ranging from 7.6 to 16 %; - RSDint ranging from 8.9 to 16 %; - RRec ranging 
from 93 to 112 %; - a limit of detection (LOD) and quantification (LOQ) of 107 and 358 
EPU/kg, respectively. 
Based on the satisfactory performance characteristics mentioned above, the CRL recommends for 
official control the single laboratory validated and further verified colorimetric methods submitted by 
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the  applicant  for  the  determination  of  the  activity  of  endo-1,4- -xylanase  in  the  feed  additive, 
premixtures and feedingstuffs. 
Further  testing  or  validation  of  the  methods to  be performed  through  the consortium  of  National 
Reference Laboratories as specified by article 10 (Commission Regulation (EC) No 378/2005) is not 
considered necessary. 